Title:
ANTIGEN-BINDING PROTEIN RECOGNIZING MAGE-A4-DERIVED PEPTIDE
Document Type and Number:
WIPO Patent Application WO/2018/225732
Kind Code:
A1
Abstract:
[Problem] To provide CAR T cells that can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used. [Solution] The problem is solved by CAR T cells for cancer therapy provided with an antibody that recognizes a MAGE-A4-derived peptide and an HLA-A2 complex, wherein the antibody has a VH amino acid sequence of SEQ ID NO: 36 and a VL amino acid sequence of SEQ ID NO: 38. In this case, the antibody preferably is provided with an amino acid sequence of SEQ ID NO: 32.
Inventors:
SHIKU HIROSHI (JP)
AKAHORI YASUSHI (JP)
KATO YUYA (JP)
MIYAHARA YOSHIHIRO (JP)
AKAHORI YASUSHI (JP)
KATO YUYA (JP)
MIYAHARA YOSHIHIRO (JP)
Application Number:
PCT/JP2018/021561
Publication Date:
December 13, 2018
Filing Date:
June 05, 2018
Export Citation:
Assignee:
UNIV MIE (JP)
International Classes:
C12N15/13; A61K35/17; A61P35/00; C07K14/47; C07K14/705; C07K16/28; C07K16/30; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/62; C12N15/63; C12N5/0783
Domestic Patent References:
| WO2013051718A1 | 2013-04-11 | |||
| WO2013051718A1 | 2013-04-11 |
Other References:
DUFFOUR, M. T. ET AL.: "A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 29, 1999, pages 3329 - 3337, XP002630782
BARRETT, JOHN: "Expanding the antigenic repertoire of CAR-T cells with ''TCR-like '' antibody specificity", CYTOTHERAPY, vol. 18, 2016, pages 929 - 930, XP055554575
MAUS, M. V. ET AL.: "Targeting Intracellular AntigensUsing Chimeric Antigen Receptors", MOLECULAR THERAPY, vol. 20, no. 1, 2012, pages S206, XP055554578
ZHANG, G. ET AL.: "Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor", SCIENTIFIC REPORTS, vol. 4, May 2015 (2015-05-01), XP055511393
MA, Q. ET AL.: "A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells", CYTOTHERAPY, vol. 18, no. 8, August 2016 (2016-08-01), pages 985 - 994, XP055554631
NAKAGAWA, TAKESHI ET AL.: "Development of next-generation adoptive immunotherapy using cytotoxic T-lymphocyte(CTL) expressing chimeric antigen-receptor(CAR)", DRUG DELIVERY SYSTEM, vol. 28, no. 1, 2013, pages 35 - 44, XP055496872
KYOGOKU, N. ET AL.: "Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene -A4 nanogel", ONCOLOGY LETTERS, vol. 12, 2016, pages 4493 - 4504, XP055554639
AKAHORI, Y. ET AL.: "Development of TCR-like scFv CAR that recognizes MAGE-A4230-239/HLA-A*02:01 complex [abstract]", CANCER SCIENCE, vol. 109, no. 1, January 2018 (2018-01-01), Yokohama, pages 102, XP009518098, [retrieved on 20180100], DOI: 10.1111/cas.13499
HUSTON ET AL., METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88
WHITLOW ET AL., PROTEIN ENG., vol. 6, 1993, pages 989
HOLLIGER ET AL., NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1126 - 36
BRENTJENS RJ ET AL.: "Safety and persistence of adoptively transferred autologous CD 19-targeted T cells in patients with relapsed or chemotherapy refractory B- leukemias", BLOOD, vol. 118, 2011, pages 4817 - 4828, XP055169039, DOI: 10.1182/blood-2011-04-348540
DAO TYAN SVEOMETT NPANKOV DZHOU LKORONTSVIT T ET AL.: "Targeting the intracellular WT1 oncogene product with a therapeutic human antibody", SCI TRANSL MED, vol. 5, 2013, pages 176ra133
VAN DER BRUGGEN PZHANG YCHAUX PSTROOBANT VPANICHELLI CSCHULTZ ESCHAPIRO JVAN DEN EYNDE BJBRASSEUR FBOON T: "Tumor-specific shared antigenic peptides recognized by human T cells", IMMUNOLOGICAL REVIEWS, vol. 188, 2002, pages 51 - 64
DUFFOUR MTCHAUX PLURQUIN CCORNELIS GBOON TVAN DER BRUGGEN P: "A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T Lymphocytes", EUR. J. IMMUNOL, vol. 29, 1999, pages 3329 - 3337, XP055554573, DOI: 10.1002/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7
MURAOKA DHARADA NHAYASHI TTAHARA YMOMOSE FSAWADA SMUKAI SAAKIYOSHI KSHIKU H: "Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity", ACS NANO., vol. 8, no. 9, 23 September 2014 (2014-09-23), pages 9209 - 18, XP055357955, DOI: 10.1021/nn502975r
HILLIG RCCOULIE PGSTROOBANT VSAENGER WZIEGLER AHUELSMEYER M: "High-resolution Structure of HLA-A*0201 in Complex with a Tumour-specific Antigenic Peptide Encoded by the MAGE-A4 Gene", J. MOL. BIOL., vol. 310, 2001, pages 1167 - 1176, XP004466111, DOI: 10.1006/jmbi.2001.4816
See also references of EP 3636761A4
BARRETT, JOHN: "Expanding the antigenic repertoire of CAR-T cells with ''TCR-like '' antibody specificity", CYTOTHERAPY, vol. 18, 2016, pages 929 - 930, XP055554575
MAUS, M. V. ET AL.: "Targeting Intracellular AntigensUsing Chimeric Antigen Receptors", MOLECULAR THERAPY, vol. 20, no. 1, 2012, pages S206, XP055554578
ZHANG, G. ET AL.: "Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor", SCIENTIFIC REPORTS, vol. 4, May 2015 (2015-05-01), XP055511393
MA, Q. ET AL.: "A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells", CYTOTHERAPY, vol. 18, no. 8, August 2016 (2016-08-01), pages 985 - 994, XP055554631
NAKAGAWA, TAKESHI ET AL.: "Development of next-generation adoptive immunotherapy using cytotoxic T-lymphocyte(CTL) expressing chimeric antigen-receptor(CAR)", DRUG DELIVERY SYSTEM, vol. 28, no. 1, 2013, pages 35 - 44, XP055496872
KYOGOKU, N. ET AL.: "Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene -A4 nanogel", ONCOLOGY LETTERS, vol. 12, 2016, pages 4493 - 4504, XP055554639
AKAHORI, Y. ET AL.: "Development of TCR-like scFv CAR that recognizes MAGE-A4230-239/HLA-A*02:01 complex [abstract]", CANCER SCIENCE, vol. 109, no. 1, January 2018 (2018-01-01), Yokohama, pages 102, XP009518098, [retrieved on 20180100], DOI: 10.1111/cas.13499
HUSTON ET AL., METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88
WHITLOW ET AL., PROTEIN ENG., vol. 6, 1993, pages 989
HOLLIGER ET AL., NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1126 - 36
BRENTJENS RJ ET AL.: "Safety and persistence of adoptively transferred autologous CD 19-targeted T cells in patients with relapsed or chemotherapy refractory B- leukemias", BLOOD, vol. 118, 2011, pages 4817 - 4828, XP055169039, DOI: 10.1182/blood-2011-04-348540
DAO TYAN SVEOMETT NPANKOV DZHOU LKORONTSVIT T ET AL.: "Targeting the intracellular WT1 oncogene product with a therapeutic human antibody", SCI TRANSL MED, vol. 5, 2013, pages 176ra133
VAN DER BRUGGEN PZHANG YCHAUX PSTROOBANT VPANICHELLI CSCHULTZ ESCHAPIRO JVAN DEN EYNDE BJBRASSEUR FBOON T: "Tumor-specific shared antigenic peptides recognized by human T cells", IMMUNOLOGICAL REVIEWS, vol. 188, 2002, pages 51 - 64
DUFFOUR MTCHAUX PLURQUIN CCORNELIS GBOON TVAN DER BRUGGEN P: "A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T Lymphocytes", EUR. J. IMMUNOL, vol. 29, 1999, pages 3329 - 3337, XP055554573, DOI: 10.1002/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7
MURAOKA DHARADA NHAYASHI TTAHARA YMOMOSE FSAWADA SMUKAI SAAKIYOSHI KSHIKU H: "Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity", ACS NANO., vol. 8, no. 9, 23 September 2014 (2014-09-23), pages 9209 - 18, XP055357955, DOI: 10.1021/nn502975r
HILLIG RCCOULIE PGSTROOBANT VSAENGER WZIEGLER AHUELSMEYER M: "High-resolution Structure of HLA-A*0201 in Complex with a Tumour-specific Antigenic Peptide Encoded by the MAGE-A4 Gene", J. MOL. BIOL., vol. 310, 2001, pages 1167 - 1176, XP004466111, DOI: 10.1006/jmbi.2001.4816
See also references of EP 3636761A4
Attorney, Agent or Firm:
KOBAYASHI, Youhei (JP)
Download PDF:
Previous Patent: VIRUS-LIKE PARTICLES TO BE USED FOR CAUSING IMMUNE RESPONSE AGAINST HBV
Next Patent: CYLINDER BORE WALL WARMING TOOL
Next Patent: CYLINDER BORE WALL WARMING TOOL